First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report
Eko Adhi Pangarsa, Putri Dwi Astuti, Daniel Rizky, Kevin Tandarto, Budi Setiawan, Andreas Agung Winarno, Damai Santosa, Catharina Suharti · 2024
Read First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report by Eko Adhi Pangarsa, Putri Dwi Astuti, Daniel Rizky, Kevin Tandarto, Budi Setiawan, Andreas Agung Winarno, Damai Santosa, Catharina Suharti (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11619148.txt.
Description
Eko Pangarsa and co-authors report a breast cancer case where hormone therapy, not chemotherapy, led the treatment in a 2024 paper. The patient, a thirty-six-year-old premenopausal woman, had luminal breast cancer that had flooded her bone marrow, a rare and dangerous spread called disseminated carcinomatosis of the bone marrow. It appears in well under one percent of metastatic cases and has no official treatment guideline.
Standard practice leans on chemotherapy, with its heavy toll, since the situation is life-threatening. This team instead opened with endocrine therapy plus a CDK 4/6 inhibitor, a drug that brakes cancer cell division and pairs with hormone treatment in this cancer type. The case shows the gentler first line in action from diagnosis in 2020. Single cases cannot set policy, but they can widen the options doctors dare to try.
Catalog record
| CREATOR | Eko Adhi Pangarsa, Putri Dwi Astuti, Daniel Rizky, Kevin Tandarto, Budi Setiawan, Andreas Agung Winarno, Damai Santosa, Catharina Suharti |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |